Drug-drug interaction study of dapagliflozin with Voglibose in Japanese type 2 diabetes mellitus patients
Study identifier:D1692C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
An Open-label, Multi-centre, Drug-drug Interaction Study to assess the effect of Voglibose (0.2 mg tid) on the Pharmacokinetics, Safety and Tolerability of single oral administration of dapagliflozin (10 mg) in Japanese Patients with Type 2 Diabetes
Medical condition
Type 2 Diabetes Mellitus
Phase
Phase 1
Healthy volunteers
No
Study drug
Dapagliflozin
Sex
All
Actual Enrollment
28
Study type
Interventional
Age
20 Years +
Date
Study Start Date: 01 Jan 2010
Primary Completion Date: 01 Apr 2010
Study Completion Date: 01 Apr 2010
Study design
Allocation: N/A
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Jan 2014 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
Bristol-Myers Squibb
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: Dapagliflozin 10mg, oral, once daily |
Contacts
Investigators
Principal Investigator
Nobuyuki Shiga
AstraZeneca
